A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis-The ASPEN Study

Project: Other project

Project Details

StatusActive
Effective start/end date10/19/2110/18/26